GTx, Inc. (NASDAQ:GTXI) insider Jason T. Shackelford sold 3,090 shares of the firm’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $11.33, for a total transaction of $35,009.70. Following the sale, the insider now owns 31,111 shares in the company, valued at $352,487.63. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
GTx, Inc. (NASDAQ:GTXI) opened at $12.16 on Wednesday. GTx, Inc. has a 52 week low of $2.73 and a 52 week high of $13.35. The company has a market cap of $254.41, a price-to-earnings ratio of -6.91 and a beta of 1.77.
GTX (NASDAQ:GTXI) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25). analysts anticipate that GTx, Inc. will post -1.61 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in GTXI. Bank of New York Mellon Corp bought a new stake in shares of GTX in the 2nd quarter worth about $124,000. Abingworth LLP bought a new stake in shares of GTX in the 3rd quarter worth about $2,781,000. Finally, Caxton Corp bought a new stake in shares of GTX in the 3rd quarter worth about $531,000. Hedge funds and other institutional investors own 11.57% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: GTx, Inc. (GTXI) Insider Sells 3,090 Shares of Stock” was originally posted by BBNS and is the property of of BBNS. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://baseballnewssource.com/markets/gtx-inc-gtxi-insider-jason-t-shackelford-sells-3090-shares-of-stock/1822653.html.
GTX Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.